{"transactions":[{"id":2665,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:12.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7657,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":85,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":7657},"source":{"system":"sec-edgar","filing":"0001140361-26-035612","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035612/form4.xml","form_type":"4"}},{"id":2664,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:12.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14461,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":41.66,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14461},"source":{"system":"sec-edgar","filing":"0001140361-26-035612","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035612/form4.xml","form_type":"4"}},{"id":2663,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:12.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10370,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":43.85,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":10370},"source":{"system":"sec-edgar","filing":"0001140361-26-035612","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035612/form4.xml","form_type":"4"}},{"id":2662,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-09-03T20:39:12.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34824,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-26-035612","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035612/form4.xml","form_type":"4"}},{"id":733060,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T22:00:11.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 25% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service."}],"balance_after":125000,"derivative":{"exercise_price":18.71,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001104659-26-075249","document":"tm2618042-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1841557/000110465926075249/tm2618042-1_4seq1.xml","form_type":"4"}},{"id":733059,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-06-17T22:00:11.000Z","date":"2026-02-05","kind":"grant","planned":false,"acquired":true,"shares":1592,"price":13.35,"value":21253.2,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Common Stock acquired under Zenas BioPharma, Inc.'s 2024 Employee Stock Purchase Plan on February 5, 2026 in transactions that were exempt under Rule 16b-3(c)."}],"balance_after":1592,"source":{"system":"sec-edgar","filing":"0001104659-26-075249","document":"tm2618042-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841557/000110465926075249/tm2618042-1_4seq1.xml","form_type":"4"}},{"id":741086,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T00:01:53.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":7657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date."}],"balance_after":7657,"derivative":{"exercise_price":85,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":7657},"source":{"system":"sec-edgar","filing":"0001104659-26-073058","document":"tm2617578-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841557/000110465926073058/tm2617578-3_4seq1.xml","form_type":"4"}},{"id":758844,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2026-05-29T20:06:13.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted under the Issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting."}],"balance_after":135000,"derivative":{"exercise_price":1.81,"expiration_date":"2036-05-28","underlying":"Class A Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001193125-26-248256","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850270/000119312526248256/ownership.xml","form_type":"4"}},{"id":1104519,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-21T00:01:12.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":14461,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date."}],"balance_after":14461,"derivative":{"exercise_price":41.66,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14461},"source":{"system":"sec-edgar","filing":"0001104659-25-061273","document":"tm2518364-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841557/000110465925061273/tm2518364-3_4seq1.xml","form_type":"4"}},{"id":1112774,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:38:35.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on June 10, 2026, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal month installments over 36 months thereafter, subject to continued service."}],"balance_after":150000,"derivative":{"exercise_price":11.94,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001104659-25-058943","document":"tm2517684-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841557/000110465925058943/tm2517684-10_4seq1.xml","form_type":"4"}},{"id":1127793,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2025-06-02T20:13:12.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":125862,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted under the Issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting."}],"balance_after":125862,"derivative":{"exercise_price":0.72,"expiration_date":"2035-05-29","underlying":"Class A Ordinary Shares","underlying_shares":125862},"source":{"system":"sec-edgar","filing":"0000950170-25-080265","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850270/000095017025080265/ownership.xml","form_type":"4"}},{"id":1326084,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-18T21:31:27.000Z","date":"2024-12-16","kind":"grant","planned":false,"acquired":true,"shares":8125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on September 12, 2025, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal month installments over 36 months thereafter, subject to continued service."}],"balance_after":8125,"derivative":{"exercise_price":8.77,"expiration_date":"2034-12-15","underlying":"Common Stock","underlying_shares":8125},"source":{"system":"sec-edgar","filing":"0001104659-24-129778","document":"tm2431489-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841557/000110465924129778/tm2431489-2_4seq1.xml","form_type":"4"}},{"id":1406302,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-17T00:48:37.000Z","date":"2024-09-12","kind":"grant","planned":false,"acquired":true,"shares":155000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on September 12, 2025, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal month installments over 36 months thereafter, subject to continued service."}],"balance_after":155000,"derivative":{"exercise_price":17,"expiration_date":"2034-09-11","underlying":"Common Stock","underlying_shares":155000},"source":{"system":"sec-edgar","filing":"0001104659-24-100326","document":"tm2424157-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841557/000110465924100326/tm2424157-5_4seq1.xml","form_type":"4"}},{"id":1415942,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2024-09-05T00:03:01.000Z","date":"2024-09-03","kind":"grant","planned":false,"acquired":true,"shares":9535,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable on July 11, 2025 subject to Ms. Fox's continued service with the Company through the applicable vesting date."}],"balance_after":9535,"derivative":{"exercise_price":2.4,"expiration_date":"2034-09-03","underlying":"Class A Ordinary Shares","underlying_shares":9535},"source":{"system":"sec-edgar","filing":"0000950170-24-103630","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850270/000095017024103630/ownership.xml","form_type":"4"}},{"id":1485968,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-08T00:03:01.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":10370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 10,370 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date."}],"balance_after":10370,"derivative":{"exercise_price":43.85,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":10370},"source":{"system":"sec-edgar","filing":"0001104659-24-069795","document":"tm2416491-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841557/000110465924069795/tm2416491-3_4seq1.xml","form_type":"4"}},{"id":1495284,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2024-06-03T20:58:47.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":62558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted under the Issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting."}],"balance_after":62558,"derivative":{"exercise_price":4.2,"expiration_date":"2034-05-30","underlying":"Class A Ordinary Shares","underlying_shares":62558},"source":{"system":"sec-edgar","filing":"0000950170-24-068072","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850270/000095017024068072/ownership.xml","form_type":"4"}},{"id":1830364,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2023-07-13T20:17:24.000Z","date":"2023-07-12","kind":"grant","planned":false,"acquired":true,"shares":42515,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest and become exercisable in two equal annual installments on July 11, 2024 and July 11, 2025 subject to Ms. Fox's continued service with the Company through the applicable vesting date."}],"balance_after":42515,"derivative":{"exercise_price":10.92,"expiration_date":"2033-07-12","underlying":"Class A Ordinary Shares","underlying_shares":42515},"source":{"system":"sec-edgar","filing":"0001209191-23-042197","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1850270/000120919123042197/doc4.xml","form_type":"4"}},{"id":1830363,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2023-07-13T20:17:24.000Z","date":"2023-07-12","kind":"grant","planned":false,"acquired":true,"shares":46632,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting subject to Ms. Fox's continued service with the Company through the applicable vesting date."}],"balance_after":46632,"derivative":{"exercise_price":10.92,"expiration_date":"2033-07-12","underlying":"Class A Ordinary Shares","underlying_shares":46632},"source":{"system":"sec-edgar","filing":"0001209191-23-042197","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850270/000120919123042197/doc4.xml","form_type":"4"}},{"id":1979869,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-02T22:58:54.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option vests as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date."}],"balance_after":600000,"derivative":{"exercise_price":1.94,"expiration_date":"2033-02-27","underlying":"Class A Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001209191-23-014885","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000120919123014885/doc4.xml","form_type":"4"}},{"id":2152781,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2022-09-22T20:37:25.000Z","date":"2022-09-20","kind":"grant","acquired":true,"shares":129370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option award vest in three equal annual installments beginning on July 11, 2023, subject to Ms. Fox's continued service as a director of the Company."}],"balance_after":129370,"derivative":{"exercise_price":9.73,"expiration_date":"2032-09-20","underlying":"Class A ordinary share","underlying_shares":129370},"source":{"system":"sec-edgar","filing":"0001209191-22-051021","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850270/000120919122051021/doc4.xml","form_type":"4"}},{"id":2170028,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-31T21:14:50.000Z","date":"2022-08-29","kind":"grant","acquired":true,"shares":480000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests as to 25% on the one year anniversary of 8/29/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date"}],"balance_after":480000,"derivative":{"exercise_price":2.93,"expiration_date":"2032-08-28","underlying":"Class A Common Stock","underlying_shares":480000},"source":{"system":"sec-edgar","filing":"0001209191-22-048148","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000120919122048148/doc4.xml","form_type":"4"}},{"id":2361192,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-02T19:32:08.000Z","date":"2022-02-28","kind":"grant","acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option vests as to 25% on the one year anniversary of 2/28/2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date"}],"balance_after":600000,"derivative":{"exercise_price":5.06,"expiration_date":"2032-02-27","underlying":"Class A Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001209191-22-014585","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000120919122014585/doc4.xml","form_type":"4"}},{"id":2863784,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-12T22:46:13.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":558506,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. (\"Panacea\") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea (\"Merger Sub\"), and Nuvation Bio Inc. (\"Legacy Nuvation\") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the \"Issuer\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in exchange for an option to purchase 558,506 shares of Legacy Nuvation Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options vest as to 20% on October 12, 2023, 20% on October 12, 2024 and 60% on October 12, 2025, subject to achievement of performance criteria."}],"balance_after":558506,"derivative":{"exercise_price":4.6,"expiration_date":"2030-10-11","underlying":"Class A Common Stock","underlying_shares":558506},"source":{"system":"sec-edgar","filing":"0001209191-21-010330","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000120919121010330/doc4.xml","form_type":"4"}},{"id":2863783,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-12T22:46:13.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":398935,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. (\"Panacea\") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea (\"Merger Sub\"), and Nuvation Bio Inc. (\"Legacy Nuvation\") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the \"Issuer\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for an option to purchase 398,935 shares of Legacy Nuvation Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options vest as to 25% on October 12, 2021 and in equal monthly installments thereafter over the following three years."}],"balance_after":398935,"derivative":{"exercise_price":4.6,"expiration_date":"2030-10-11","underlying":"Class A Common Stock","underlying_shares":398935},"source":{"system":"sec-edgar","filing":"0001209191-21-010330","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000120919121010330/doc4.xml","form_type":"4"}}]}